IP5-MATTER Trial

This account has been archived, please follow @IP_London for future #IP5MATTER updates

[IP5-MATTER Trial @MatterTrial]

📢 Our clinical trial accounts are being archived - please follow @IP_London for future #IP5MATTER updates

#UrSoMe

[Imperial Prostate @IP_London]

Kicking off 2022 in @EurUrolOpen.

With cytoreductive prostatectomy, radiotherapy, ablation, SABR...

What are patients' values, preferences and expectations for the treatment of metastatic PCa?

@VWatsonEcon @mesfin_genie @Connor_Urol @LondonProstate1

https://t.co/nPdRYYxC5F

[IP5-MATTER Trial @MatterTrial]

👋IP5-MATTER trial protocol published in @BMJ_Open this week.

Recruiting in 30 NHS centres-ahead of schedule, results due in 2022.

Congrats to the huge UK effort @IP_London @HERU_Abdn @VWatsonEcon @Connor_Urol @LondonProstate1 @wellcometrust

https://t.co/XgBL1Co1Sx

[Paperbirds_Oncology @PaperbirdsO]

New article: Metastatic prostate cancer men's attitudes towards treatment of the local tumour and metastasis evaluative research (IP5-MATTER): protocol for a prospective, multicentre discrete choice experiment study https://t.co/vJMGmRSSVf #prostatecancer #oncology

[Hashim U. Ahmed @LondonProstate1]

Well done Martin on a nice article summarising trials in cytoreductive surgery in metastatic prostate cancer in @Uro_News
@IP_London
@timdudderidge
@stingrai78
@Connor_Urol
@SageOfLondon1
@AtlantaIp2 @MatterTrial

[Imperial Prostate @IP_London]

@LondonProstate1 @Uro_News @timdudderidge @stingrai78 @Connor_Urol @SageOfLondon1 @AtlantaIp2 @MatterTrial Check out the full text FREE here --> https://t.co/RG76pgmpXZ

@Uro_News @AtlantaIp2 @MatterTrial

[IP5-MATTER Trial @MatterTrial]

A very warm welcome to the IP5-Matter trial for Dr Alison Reid’s team at the Kingston Hospital NHS Foundation Trust! Great to have you with us! @KingstonHospNHS @connor_urol @londonprostate1 @uclhcharity @wellcome @IP_London

[IP5-MATTER Trial @MatterTrial]

A huge congratulations to our top recruiter in September for IP-5 Matter.
Well done East Surrey Hospital for recruiting 4 patients! Amazing work!
@connor_urol @londonprostate1 @uclhcharity @wellcome @IP_London
👏👏👏

[Martin J. Connor @Connor_Urol]

MRI findings in de novo synchronous metastatic prostate cancer - what are the implications for cytoreductive prostatectomy?

Sad not to be able to give this #Podium session at #AUA21 in Las Vegas, but honoured to be able to present my early PhD work virtually
@AmerUrological

[IP5-MATTER Trial @MatterTrial]

IP5-MATTER Exceeds national recruitment target for the first 7 months!

Huge congratulations to all our hard-working NHS sites with a special mention to our top recruiting team at King’s Lynn, Cambridge! Amazing Work!

@IP_London

[Martin J. Connor @Connor_Urol]

Really great to be able to share our early results with #EAU21 audience.

Thanks to all the hard work from @IP_London @LondonProstate1 clinical trial team and our expert health economists @HERU_Abdn @VWatsonEcon @mesfin_genie for opening during covid!

https://t.co/yNurWVUDfP

[IP5-MATTER Trial @MatterTrial]

Our lead @Connor_Urol presenting IP5-MATTER trial updated at #EAU21.

Open in 22 centres with recruitment ahead of schedule! Thanks to everyone supporting this study -
@wellcometrust @UCLHCharity @LondonProstate1 @IP_London @ImperialSandC @NIHRCRN_NWLdn
https://t.co/caQvpYKpz8

[Hashim U. Ahmed @LondonProstate1]

Important paradigm to evaluate in the IP2-ATLANTA RCT with patient trade-offs evaluated in IP5-MATTER
@MatterTrial #EAU21 #EAU2021 @IP_London @AtlantaIp2 @MatterTrial @HERU_Abdn @VWatsonEcon @Connor_Urol @NIHRresearch @NCRI_partners

[Imperial Prostate @IP_London]

Congratulations to the IP5-MATTER Trial, We hear that 21 / 30 sites will be open by the end of May.

Great to offer this charity funded academic study across England, Wales and Scotland

@MatterTrial @UCLHCharity @wellcometrust @HERU_Abdn

[IP5-MATTER Trial @MatterTrial]

🔊 🔊 IP5-MATTER Exceeds national recruitment target for the first 3-months !

Massive well done to all our UK NHS sites, especially to the top 3 super recruiters:

1. West Middlesex University Hospital
2. Royal United Hospitals Bath
3. King's Lynn, Cambridge

@IP_London

[HERU @HERU_Abdn]

New @HERU_Abdn blog posted on the IP5-MATTER TRIAL, led by @Connor_Urol @IP_London, and our development of a choice experiment (DCE) to identify the treatment preferences of men with newly diagnosed metastatic prostate cancer @MatterTrial @LondonProstate1 https://t.co/smX3zpaMkS

[Imperial Prostate @IP_London]

A lovely summary on the development of a choice experiment for men with advanced prostate cancer @HERU_Abdn

@MatterTrial up to 17 UK NHS sites and exceeding recruitment we cant wait to see results of the IP5 study! @VWatsonEcon @mesfin_genie @LondonProstate1 @Connor_Urol

[Imperial Prostate @IP_London]

Nice work @MatterTrial look forward to seeing the early progress of this multicentre UK charity-funded study on treatment choices in newly diagnosed metastatic prostate cancer!

[IP5-MATTER Trial @MatterTrial]

📢We are very excited to be able to share @MatterTrial progress with you, accepted as a trials-in-progress abstract @Uroweb #EAU21 annual congress!

Congratulations to all the co-authors & funders @wellcometrust @UCLHCharity @HERU_Abdn @Connor_Urol @VWatsonEcon @LondonProstate1

[IP2 - ATLANTA Trial @AtlantaIp2]

Well done for getting this academic charity funded study open @MatterTrial team!

Great to see @UHSFT offering another prostate cancer study to local patients @NIHRCRNWessex